Medicare Expands Coverage for Obesity Drugs With $50 Monthly Copay Through 2027

Medicare has announced a temporary expansion of coverage for weight-loss medications, allowing beneficiaries to access popular obesity drugs for a $50 monthly copay, according to the Centers for Medicare & Medicaid Services (CMS). The policy, effective immediately, applies to specific medications and requires patients to meet clinical criteria, with the measure set to expire in 2027.

What Medications Are Covered Under the New Policy?

The CMS has not yet released an official list of covered drugs, but the expansion aligns with the agency’s 2023 decision to include certain FDA-approved weight-loss medications under Medicare Part D and Medicare Advantage plans. These typically include drugs like semaglutide (Wegovy), liraglutide (Saxenda), and orlistat, which are used for chronic weight management in patients with a body mass index (BMI) of 25 or higher, according to the American Medical Association (AMA).

Who Qualifies for the Coverage?

Beneficiaries must meet specific medical criteria to access the drugs, including a diagnosis of obesity and a BMI of 25 or higher, as outlined in CMS guidelines. Patients must also receive a prescription from a licensed healthcare provider and participate in a structured weight-management program, according to a 2023 CMS fact sheet. The requirement for behavioral counseling or nutrition guidance is intended to ensure the medications are used as part of a comprehensive treatment plan.

How Long Will the Policy Last?

The expanded coverage is a temporary measure set to expire on December 31, 2027, as part of a broader effort to evaluate the long-term effectiveness and cost implications of obesity drug coverage. CMS spokespersons have stated that the agency will review the program’s impact before determining its future, per a February 2024 report in The New York Times.

Why Is This Policy Significant?

The move reflects growing recognition of obesity as a chronic medical condition rather than a lifestyle choice, according to Dr. Rachel K. Johnson, a professor of nutrition at the University of Vermont. “By expanding access to evidence-based treatments, Medicare is addressing a critical public health issue,” she said in a 2023 interview with Health Affairs. The policy also aligns with the 2021 national obesity strategy launched by the Biden administration, which emphasized improving access to preventive care and medications.

What Are the Cost Implications for Beneficiaries?

While the $50 copay is significantly lower than typical out-of-pocket costs for obesity medications, which can exceed $1,000 per month, the policy excludes certain high-cost drugs. For example, semaglutide, which has been shown to reduce body weight by 15% on average, remains subject to standard plan formularies, according to a 2024 analysis by the Kaiser Family Foundation (KFF). Patients with Medicare Advantage plans may face additional restrictions based on their specific plan’s coverage.

How Does This Compare to Previous Policies?

Before 2023, Medicare generally did not cover weight-loss medications unless they were used for specific conditions like type 2 diabetes. The 2023 expansion marks a shift toward broader coverage for obesity, following similar moves by private insurers and state Medicaid programs. For instance, California’s Medi-Cal program expanded coverage for obesity drugs in 2022, according to a 2023 report by the Commonwealth Fund.

What Are the Potential Challenges?

Healthcare providers have raised concerns about the administrative burden of verifying eligibility and documenting patient progress for the structured weight-management programs. Additionally, some experts caution that the temporary nature of the policy may limit its long-term impact on obesity rates, as noted in a 2024 editorial in JAMA Internal Medicine. “Sustained access to these medications is critical for meaningful public health outcomes,” the editorial stated.

Key Takeaways

• Medicare beneficiaries can access certain obesity drugs for a $50 monthly copay through 2027.
• Coverage requires meeting clinical criteria, including a BMI of 25 or higher and participation in a weight-management program.
• The policy is part of a broader effort to address obesity as a chronic condition but remains temporary.
• Costs and coverage may vary by plan, with some high-cost medications excluded.